Want to see VTRS full AI Analyst Report?
VTRS Stock Chart & Stats
$17.24
-$0.04(-0.23%)
At close: 4:00 PM EDT
$17.24
-$0.04(-0.23%)
Day’s Range― - ―
52-Week Range$9.43 - $18.39
Previous CloseN/A
Volume7.37M
Average Volume (3M)9.48M
Market Cap
$18.52B
Enterprise Value$30.69K
Total Cash (Recent Filing)$1.51B
Total Debt (Recent Filing)$13.63B
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 09, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend Yield2.94%
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,148,590,800
10 Day Avg. Volume8,837,165
30 Day Avg. Volume9,482,366
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.17Price Target Upside5.38% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.49
Revenue Forecast (FY)$14.78B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow provides internal funding for debt reduction, product investment and shareholder returns. The ability to generate substantial cash despite reported losses also indicates that the core commercial model and working-capital discipline remain valuable.
Raised Outlook And Improving MarginsA raised outlook after a quarterly beat supports confidence in execution and suggests that cost discipline and portfolio actions can sustain adjusted earnings improvement. The 57.5% adjusted gross margin, up nearly one percentage point year over year, reinforces operating leverage.
Pipeline And Portfolio BreadthA broad pipeline spanning complex generics, specialty products and biosimilars can reduce dependence on mature products facing price erosion. Regulatory progress and numerous planned approvals create opportunities to refresh the portfolio and improve mix over the next several years.
Bears Say
Persistent Bottom-line LossesNegative operating profit and net income weaken the quality and predictability of shareholder returns, even with strong cash flow. Multi-year earnings volatility and declining gross margin suggest that pricing, product mix or costs may continue to constrain sustainable GAAP profitability.
Nashik Supply DisruptionThe facility fire, inspection observations and remediation requirements create execution risk beyond a single reporting period. Supply interruptions can reduce customer reliability, delay product availability and pressure revenue while the company restores production and regulatory compliance.
Competitive And Policy PressureGeneric and branded-generic markets remain exposed to price competition, while procurement changes can weaken access and volumes in China. These pressures may persist because rivals and public purchasing systems can structurally limit pricing power and moderate growth in key products.
Viatris News
VTRS FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was $9.43 and its highest was $18.39 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is $18.52B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 79 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on Aug 06, 2026. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.601 by $0.089.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 2.94%. See more information on Viatris, Inc. dividends here
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.65.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,148,590,800 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of $0.69 in its last earnings report, beating expectations of $0.601. Following the earnings report the stock price went down -7.706%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.17 (5.38% Upside)
$18.17 (5.38% Upside)
Blogger Sentiment
Neutral
VTRS Sentiment 55%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 147.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.66%
12-Months-Change
Fundamentals
Return on Equity
2.94%
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
VTRS Company Deck
VTRS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.View all VTRS earnings summariesVTRS Net sales Breakdown
64.45% Brands
35.55% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$18.17
▲(5.38% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
0.28% Insiders
27.80% Mutual Funds
20.70% Other Institutional Investors
23.66% Public Companies and
Individual Investors